Abstract
HY-133 is a recombinant bacteriophage endolysin with bactericidal activity againstStaphylococcus aureus Here, HY-133 showedin vitroactivity against major African methicillin-susceptible and methicillin-resistantS. aureuslineages and ceftaroline/ceftobiprole- and borderline oxacillin-resistant isolates. HY-133 was also active againstStaphylococcus schweitzeri, a recently described species of theS. aureuscomplex. The activity of HY-133 on the tested isolates (MIC50, 0.25 μg/ml; MIC90, 0.5 μg/ml; range, 0.125 to 0.5 μg/ml) was independent of the species and strain background or antibiotic resistance.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Africa
-
Anti-Bacterial Agents / biosynthesis
-
Anti-Bacterial Agents / pharmacology*
-
Ceftaroline
-
Cephalosporins / pharmacology
-
Endopeptidases / biosynthesis
-
Endopeptidases / genetics
-
Endopeptidases / pharmacology*
-
Humans
-
Methicillin Resistance / genetics
-
Microbial Sensitivity Tests
-
Recombinant Proteins / biosynthesis
-
Recombinant Proteins / genetics
-
Recombinant Proteins / pharmacology*
-
Staphylococcal Infections / microbiology
-
Staphylococcus / drug effects*
-
Staphylococcus / growth & development
-
Staphylococcus / isolation & purification
-
Staphylococcus Phages / metabolism*
-
Staphylococcus aureus / drug effects*
-
Staphylococcus aureus / growth & development
-
Staphylococcus aureus / isolation & purification
-
beta-Lactam Resistance / genetics
Substances
-
Anti-Bacterial Agents
-
Cephalosporins
-
Recombinant Proteins
-
ceftobiprole
-
Endopeptidases
-
endolysin
Grants and funding
The study was supported in part by the BMBF-DZIF (German Center for Infection Research, TTU 08.807).